Introduction
MPM, tumor, breast cancers, cancer, MPEs
NON-SMALL CELL LUNG CANCER, TUMOR, VIRUS, BREAST CANCER, CANCER, DISEASE, METASTATIC DISEASE, CYTOPATHIC EFFECTS, VACCINIA, CAVITY, MALIGNANT PLEURAL MESOTHELIOMA, MALIGNANT PLEURAL EFFUSIONS, METASTATIC NON-SMALL CELL LUNG CANCER
With an estimated annual incidence of at least 150,000 patients in the United States, malignant pleural effusions (MPEs) occur in 15% of all patients with cancer during the course of their disease (Malignant pleural mesothelioma (MPM), metastatic non-small cell lung cancer, and breast cancers are common causes of MPEs. Malignant pleural mesothelioma is a rare cancer with diffuse involvement of the pleural cavity. Immune checkpoint inhibitors have shown promising results in patients with MPM; however, the increase in survival is limited to mostly biphasic and sarcomatoid forms of MPM (Oncolytic viruses, which selectively infect and exert cytopathic effects on tumor cells, are a potential therapeutic option for MPM. As a member of the poxvirus family of the genus orthopoxvirus, the vaccinia virus is one such oncolytic virus that possesses multiple favorable features for use as a therapeutic agent. It exhibits rapid cell-to-cell spread, is cytolytic across a broad range of tumor cell types, has a large insertion capacity for exogenous genes, and is genetically stable with low potential for mutagenesis (In We conducted a single-center phase I clinical trial (NCT01766739) to study the intrapleural administration of attenuated vaccinia virus (GL-ONC1, Genelux Corporation) in patients with MPEs due to MPM or metastatic disease (non-small cell lung cancer or breast cancer). In 2019, the United States Adopted Names Council (USAN) granted Genelux adoption of the name 